| Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests C Cobelli, GM Toffolo, CD Man, M Campioni, P Denti, A Caumo, P Butler, ... American Journal of Physiology-Endocrinology and Metabolism 293 (1), E1-E15, 2007 | 406 | 2007 |
| The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampicin concentrations: dosing implications E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ... Antimicrobial agents and chemotherapy, AAC. 01833-10, 2011 | 173* | 2011 |
| Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines H McIlleron, R Rustomjee, M Vahedi, T Mthiyane, P Denti, C Connolly, ... Antimicrobial agents and chemotherapy 56 (6), 3232-3238, 2012 | 123 | 2012 |
| Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. P Denti, K Jeremiah, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ... PloS one 10 (10), e0141002, 2015 | 118 | 2015 |
| Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection KE Dooley, P Denti, N Martinson, S Cohn, F Mashabela, J Hoffmann, ... The Journal of infectious diseases 211 (2), 197-205, 2015 | 104 | 2015 |
| Characterizing multisegment foot kinematics during gait in diabetic foot patients Z Sawacha, G Cristoferi, G Guarneri, S Corazza, G Donà, P Denti, ... Journal of neuroengineering and rehabilitation 6, 37, 2009 | 100 | 2009 |
| Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction MT Chirehwa, R Rustomjee, T Mthiyane, P Onyebujoh, P Smith, ... Antimicrobial agents and chemotherapy 60 (1), 487-494, 2016 | 90 | 2016 |
| Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ... Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014 | 78 | 2014 |
| Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs MGG Sturkenboom, AG Märtson, EM Svensson, DJ Sloan, KE Dooley, ... Clinical pharmacokinetics 60 (6), 685-710, 2021 | 74 | 2021 |
| UCT943, a next-generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria C Brunschwig, N Lawrence, D Taylor, E Abay, M Njoroge, GS Basarab, ... Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 00012-18, 2018 | 72 | 2018 |
| A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs A Daskapan, LR Idrus, MJ Postma, B Wilffert, JGW Kosterink, Y Stienstra, ... Clinical pharmacokinetics 58 (6), 747-766, 2019 | 71 | 2019 |
| Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV K Jeremiah, P Denti, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ... Antimicrobial agents and chemotherapy 58 (6), 3468-3474, 2014 | 71 | 2014 |
| Clinical standards for the dosing and management of TB drugs JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ... The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022 | 64 | 2022 |
| Delayed sputum culture conversion in TB-HIV co-infected patients with low isoniazid and rifampicin concentrations C Sekaggya-Wiltshire, A von Braun, M Lamorde, B Ledergerber, ... Clinical Infectious Diseases, 2018 | 58* | 2018 |
| Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in … K Singh, J Okombo, C Brunschwig, F Ndubi, L Barnard, C Wilkinson, ... Journal of medicinal chemistry 60 (4), 1432-1448, 2017 | 58 | 2017 |
| Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients SP Zvada, P Denti, FA Sirgel, E Chigutsa, M Hatherill, S Charalambous, ... Antimicrobial agents and chemotherapy 58 (1), 503-510, 2014 | 58 | 2014 |
| Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB A Naidoo, M Chirehwa, H McIlleron, K Naidoo, S Essack, N Yende-Zuma, ... Journal of Antimicrobial Chemotherapy 72 (5), 1441-1449, 2017 | 57 | 2017 |
| Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis P Denti, AJ Garcia-Prats, HR Draper, L Wiesner, J Winckler, S Thee, ... Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 01521-17, 2018 | 54 | 2018 |
| Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis N Rockwood, JG Pasipanodya, P Denti, F Sirgel, M Lesosky, T Gumbo, ... Clinical Infectious Diseases 64 (10), 1350-1359, 2017 | 54 | 2017 |
| Antimalarial and anticancer activities of artemisinin–quinoline hybrid-dimers and pharmacokinetic properties in mice MC Lombard, DD N’Da, JC Breytenbach, NI Kolesnikova, CT Van Ba, ... European Journal of Pharmaceutical Sciences 47 (5), 834-841, 2012 | 50 | 2012 |
Helen McIlleronVerified email at uct.ac.za